Skip to main content
OpenTrials
Completed

NCT Number: NCT01360060

Analgesia After Cesarean Section

Magnesium sulphate is the first line therapy for the management of preeclampsia and eclampsia in obstetrics. Perioperative administration of magnesium sulphate has been proved to be an effective as an analgesic adjuvant. The investigators evaluated the analgesic effect of magnesium in parturients undergoing Cesarean section.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–50 year

Sex eligibility

Female

Study type

Observational

Primary location

Seoul national university bundang hospital

Seongnam-si, Gyeonggi-do, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • parturients undergoing Cesarean section

Treatment and study plan

Magnesium sulphate

Drug

Magnesium sulphate was infused for the management of preeclampsia at perioperative period.

Primary outcomes

  1. Change of numeric rating scale (NRS) of postoperative pain during postoperative period

    Time frame: postoperative 1, 2, 3, and 4 day

Secondary outcomes

  1. incidence of stopping of intravenous PCA during postoperative 4 days

    Time frame: during postoperative 4 days

  2. serum magnesium level of group P

    Time frame: preoperative 1 h and postoperative 1 day

Sponsors and collaborators

Lead sponsor

Seoul National University Bundang Hospital

Other

Registry information

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
May 25, 2011
Registry last updated
May 25, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.